

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

EXTENSION OF COMPLETION DATE OF MAJOR TRANSACTION IN RELATION TO DEEMED DISPOSAL OF EQUITY INTEREST IN HENAN FUSEN PHARMACEUTICAL COMPANY LIMITED

Reference is made to the announcement and the circular (the “**Circular**”) of Fusen Pharmaceutical Company Limited (the “**Company**”) dated 18 June 2026 and 23 June 2026, respectively, in relation to, among other things, the Capital Increase. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

Extension of Completion Date

As disclosed in the Circular, under the Capital Increase Agreement, the conditions precedent to the Capital Increase set out in the Circular (the “**Conditions Precedent**”) were required to be satisfied or waived (where applicable) on or before 2 August 2026. All the Conditions Precedent have been fulfilled as at the date of this announcement. Following the satisfaction of all the Conditions Precedent and the issuance of the Payment Notice to the Investors, the Investors were required to pay the Capital Increase Price within five Business Days, upon which completion of the Capital Increase (“**Completion**”) would take place. Accordingly, under the original timetable provided under the Capital Increase Agreement, Completion was required to take place no later than 7 August 2026.

As additional time is required for the Investors to complete the internal arrangements necessary for payment of the Capital Increase Price for Completion, the Investors, Nanyang Hengsheng, Wealth Depot (HK) and the Target Company mutually agree to extend the Capital Increase Price Payment Date to a date falling on or before 8 October 2026 pursuant to a supplemental agreement to the Capital Increase Agreement dated 30 July 2026.

Save as disclosed above, all other terms and conditions of the Capital Increase Agreement remain unchanged and continue in full force and effect.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Zhiming
Chairman and Executive Director

Hong Kong, 30 July 2026

As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors, and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive Directors.